跳至主要内容
临床试验/NCT00016445
NCT00016445已完成2 期

Phase II Study of Growth Hormone in Children With Cystic Fibrosis

University of Utah18 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2001年2月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
40
试验地点
18

研究概览

简要总结

OBJECTIVES: I. Determine the effect of growth hormone on height, height velocity, body weight, and lean body mass in patients with cystic fibrosis.

II. Determine the effect of growth hormone on pulmonary function in these patients.

III. Determine the impact of this drug on the quality of life in these patients.

IV. Determine if the clinical response from this drug is sustained in these patients.

详细描述

PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive growth hormone subcutaneously (SC) daily for 1 year during the first year only.

Arm II: Patients receive growth hormone SC daily for 1 year during the second year only.

Quality of life is assessed at baseline and then every 6 months for 2 years.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
5 Years 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Other

研究点 (18)

Loading locations...

相似试验